These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 36216148)

  • 21. The role of neoantigens in tumor immunotherapy.
    Shang S; Zhao Y; Qian K; Qin Y; Zhang X; Li T; Shan L; Wei M; Xi J; Tang B
    Biomed Pharmacother; 2022 Jul; 151():113118. PubMed ID: 35623169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
    Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
    J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
    Yoo HJ; Harapan BN
    Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural Killer Cell-Based Immunotherapy against Glioblastoma.
    Morimoto T; Nakazawa T; Maeoka R; Nakagawa I; Tsujimura T; Matsuda R
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
    Neagu MR; Reardon DA
    Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells.
    Chokshi CR; Shaikh MV; Brakel B; Rossotti MA; Tieu D; Maich W; Anand A; Chafe SC; Zhai K; Suk Y; Kieliszek AM; Miletic P; Mikolajewicz N; Chen D; McNicol JD; Chan K; Tong AHY; Kuhlmann L; Liu L; Alizada Z; Mobilio D; Tatari N; Savage N; Aghaei N; Grewal S; Puri A; Subapanditha M; McKenna D; Ignatchenko V; Salamoun JM; Kwiecien JM; Wipf P; Sharlow ER; Provias JP; Lu JQ; Lazo JS; Kislinger T; Lu Y; Brown KR; Venugopal C; Henry KA; Moffat J; Singh SK
    Nat Med; 2024 Oct; 30(10):2936-2946. PubMed ID: 39095594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
    Lin YJ; Mashouf LA; Lim M
    Front Immunol; 2022; 13():817296. PubMed ID: 35265074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations for personalized neoantigen vaccination in Malignant glioma.
    Dunn GP; Sherpa N; Manyanga J; Johanns TM
    Adv Drug Deliv Rev; 2022 Jul; 186():114312. PubMed ID: 35487282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators.
    Segura-Collar B; Hiller-Vallina S; de Dios O; Caamaño-Moreno M; Mondejar-Ruescas L; Sepulveda-Sanchez JM; Gargini R
    Acta Neuropathol Commun; 2023 May; 11(1):79. PubMed ID: 37165457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
    Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
    Front Immunol; 2022; 13():867154. PubMed ID: 35603195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Research progress of neoantigens in gynecologic cancers.
    Song Y; Zhang Y
    Int Immunopharmacol; 2022 Nov; 112():109236. PubMed ID: 36113318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
    Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
    Jindal V
    Mol Neurobiol; 2018 Nov; 55(11):8236-8242. PubMed ID: 29524050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
    Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
    J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
    Choi BD; Curry WT; Carter BS; Maus MV
    Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoantigen-directed therapeutics in the clinic: where are we?
    Lybaert L; Thielemans K; Feldman SA; van der Burg SH; Bogaert C; Ott PA
    Trends Cancer; 2023 Jun; 9(6):503-519. PubMed ID: 37055237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoantigens and their clinical applications in human gastrointestinal cancers.
    Eshkiki ZS; Agah S; Tabaeian SP; Sedaghat M; Dana F; Talebi A; Akbari A
    World J Surg Oncol; 2022 Sep; 20(1):321. PubMed ID: 36171610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.